<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038038</url>
  </required_header>
  <id_info>
    <org_study_id>ID93-028</org_study_id>
    <nct_id>NCT00038038</nct_id>
  </id_info>
  <brief_title>Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole</brief_title>
  <official_title>Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to answer the following questions using&#xD;
      18F-fluoromisonidazole as an imaging agent:&#xD;
&#xD;
        1. Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)?&#xD;
&#xD;
        2. If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to&#xD;
           control human tumors?&#xD;
&#xD;
        3. Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic (low oxygen) cells have long been known to exist in animal tumors. It is also known&#xD;
      that hypoxic cells are more difficult to eliminate with radiotherapy than tumor cells at&#xD;
      normal levels of oxygen (normoxic cells). However, the extent to which hypoxic cells limit&#xD;
      the curability of human tumors is uncertain. To determine if hypoxic cells exist in human&#xD;
      tumors and how hypoxic cells might influence the efficacy of radiotherapy, this study&#xD;
      involves direct measurements of oxygen levels in human tumors compared to the tumor uptake of&#xD;
      the experimental drug, 18F-fluoromisonidazole (18F-FMISO), visualized with PET scanning.&#xD;
      18F-fluoromisonidazole has been used with PET imaging to tell the difference between growing&#xD;
      tumors which have high and low oxygen content.&#xD;
&#xD;
      Before beginning radiotherapy, a PET scan (series of pictures, 20 min. scan) will be&#xD;
      performed at 2 hours after an intravenous injection of a small amount of radioactive traces&#xD;
      drug, 18F-fluoromisonidazole (18F-FMISO) to observe the active hypoxia tumors areas. Upon&#xD;
      completion of the 18F-FMISO PET scan, direct oxygen measurements will be obtained by placing&#xD;
      a small needle into the tumor under computer tomographic (CT) guidance. The PET scan and&#xD;
      needle measurements will be repeated every 4 weeks into the course of radiotherapy and again&#xD;
      after the completion of radiotherapy. The measurement obtained by 18F-FMISO PET scanning&#xD;
      (non-invasive technique) and by direct needle measurements (invasive technique) will be&#xD;
      correlated with the eventual treatment outcome for future use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled, study terminated.&#xD;
  </why_stopped>
  <start_date>January 1994</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Direct Oxygen Measurements</measure>
    <time_frame>PET scan and needle measurements will be repeated every 4 weeks into the course of radiotherapy and again after the completion of radiotherapy.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Metastases, Neoplasm</condition>
  <arm_group>
    <arm_group_label>PET + 18F-fluoromisonidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-fluoromisonidazole</intervention_name>
    <description>Small amount of radioactive traces drug given by intravenous injection prior to PET Scan</description>
    <arm_group_label>PET + 18F-fluoromisonidazole</arm_group_label>
    <other_name>18F-FMISO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection</description>
    <arm_group_label>PET + 18F-fluoromisonidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of head and neck wth metastatic neck&#xD;
             nodes greater than or equal to 2cm&#xD;
&#xD;
          -  Karnofsky performance status greater or equal to 60%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior irradiation or surgery to head/neck area&#xD;
&#xD;
          -  No prior chemotherapy within 1 month of participation and have recovered from&#xD;
             associated related effects&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Any intercurrent medical or physiologic disorder which would prevent informed consent&#xD;
&#xD;
          -  Underlying medical problems which would compromise technical ability to deliver a&#xD;
             &quot;standard course&quot; of radiation therapy&#xD;
&#xD;
          -  Patients with PT or PTT over 1.5 times normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald A Podoloff, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 24, 2002</study_first_submitted>
  <study_first_submitted_qc>May 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2002</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous cell carcinoma of head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

